Stocks Health care CLPT
NASDAQ · Health careClearPoint Neuro, Inc. (CLPT)
ClearPoint Neuro, Inc. brought in $45.5M of revenue over the twelve months to September 30, 2026, up 32.5% from a year earlier. It posted a net loss of $36.1M. In fiscal 2025 capital spending exceeded operating cash flow by $24.4M. At September 30, 2026 it held $46.2M in cash against $50.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 28, 2026.
Key facts about ClearPoint Neuro, Inc.
- Net worth
- ClearPoint Neuro, Inc. has a market value (market cap) of $267.5M at the latest share price, and shareholders' equity of $27.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $37M (+17.8% year on year), with a net loss of $25.5M. Over the 12 months to September 30, 2026: revenue $45.5M, net loss $36.1M.
- Cash flow
- In fiscal 2025 operations used $23.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 28, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- ClearPoint Neuro, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What ClearPoint Neuro, Inc. does
ClearPoint Neuro, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker CLPT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $37M | -$25.5M | -$0.90 | -$24.4M |
| 2024 | $31.4M | -$18.9M | -$0.70 | -$9.2M |
| 2023 | $24M | -$22.1M | -$0.90 | -$14.4M |
| 2022 | $20.6M | -$16.4M | -$0.68 | -$16.4M |
| 2021 | $16.3M | -$14.4M | -$0.69 | -$12.9M |
| 2020 | $12.8M | -$6.8M | -$0.43 | -$7.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CLPT ranks in Health care
Latest SEC filings
What ClearPoint Neuro, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Passive stake changed SCHEDULE 13G/A
- October 28, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 36% to $12.1M versus the same quarter last year; diluted EPS -$0.24 versus -$0.21.
- October 28, 2026
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 18% to $10.9M versus the same quarter last year; diluted EPS -$0.38 versus -$0.21.
- August 3, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- May 21, 2026
- May 20, 2026
Insider trades
What the people running ClearPoint Neuro, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Fletcher R JohnDirector | Received as pay | 993 | $12.1K |
| October 1, 2026 | Richards Timothy T.Director | Received as pay | 319 | $3.9K |
| September 2, 2026 | Burnett JosephCEO and President, Director | Exercised options | 12,517 | $43.4K |
| July 1, 2026 | Richards Timothy T.Director | Received as pay | 222 | $4K |
| July 1, 2026 | Fletcher R JohnDirector | Received as pay | 662 | $11.8K |
| June 30, 2026 | Burnett JosephCEO and President, Director | Received as pay | 1,361 | $16.2K |
| June 30, 2026 | D'Alessandro DaniloChief Financial Officer | Received as pay | 1,085 | $12.9K |
| June 30, 2026 | Stigall L. JeremyChief Business Officer | Received as pay | 1,781 | $21.2K |
Who owns CLPT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bigger Michael13G, passive with 7 related filers | 8.12% | November 3, 2026 |
| Mak Capital One LLC13G, passive with 2 related filers | 7.8% | August 12, 2026 |
| MAK Capital Fund LP13G, passive with 2 related filers | 6.3% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 129 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 2,379,804 | +297,054 |
| Mak Capital One LLC | 2,375,861 | +474,372 |
| Vanguard Capital Management LLC | 1,232,807 | -10,808 |
| State Street Corp | 816,547 | +136,728 |
| Geode Capital Management, LLC | 749,932 | +44,212 |
| Lane Generational LLC | 444,831 | -42,018 |
| UBS Group AG | 428,632 | -3,728 |
| Millennium Management LLC | 357,676 | +125,702 |
| Brown Advisory Inc | 325,906 | 0 |
| Compass Financial Management LLC | 295,680 | new |
| Susquehanna International Group, Llp | 240,282 | +103,998 |
| Northern Trust Corp | 230,986 | +21,560 |
| Pier Capital, LLC | 222,761 | new |
| Vanguard Fiduciary Trust Co | 213,246 | +7,491 |
| Vanguard Portfolio Management LLC | 194,584 | -90,225 |
| Tudor Investment Corp ET AL | 173,759 | +16,788 |
| Morgan Stanley | 165,786 | +35,914 |
| Two Sigma Investments, LP | 154,851 | -55,929 |
| Bank of New York Mellon Corp | 151,767 | +8,020 |
| Parsons Capital Management Inc | 148,976 | -194 |
Insiders
11 insiders reported holding 1,165,052 shares in total, about $10.2M at the last price.
| Holder | Shares |
|---|---|
| Burnett JosephCEO and President, Director | 322,108191,388 held indirectly |
| Fletcher R JohnDirector | 132,004 |
| Girin Pascal E RDirector | 110,623 |
| Stigall L. JeremyChief Business Officer | 110,263 |
| D'Alessandro DaniloChief Financial Officer | 103,769 |
| Richards Timothy T.Director | 87,863 |
| Johnson B KristineDirector | 71,116 |
| Sabra MazinChief Operating Officer | 67,343 |
| Liau Linda M.Director | 64,801 |
| Fallon Lynnette CDirector | 48,227 |
Questions about CLPT
What does ClearPoint Neuro, Inc. do?
ClearPoint Neuro, Inc. is a company in the Health care sector, listed on NASDAQ as CLPT. Its shares trade on NASDAQ under the ticker CLPT.
What is ClearPoint Neuro, Inc.'s net worth?
ClearPoint Neuro, Inc. has a market value (market cap) of $267.5M at the latest share price, and shareholders' equity of $27.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is ClearPoint Neuro, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $36.1M on revenue of $45.5M.
How much revenue does ClearPoint Neuro, Inc. make?
Over the twelve months to September 30, 2026 ClearPoint Neuro, Inc. reported revenue of $45.5M. That is 32.5% more than a year earlier.
When did ClearPoint Neuro, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 28, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 3, 2026.
When is ClearPoint Neuro, Inc.'s next earnings report?
ClearPoint Neuro, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CLPT with
Follow CLPT
Get an email when ClearPoint Neuro, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values ClearPoint Neuro, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.